TWD 16.9
(0.0%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 796.6 Million TWD | -4.94% |
2022 | 838.04 Million TWD | -32.82% |
2021 | 1.24 Billion TWD | 24.39% |
2020 | 1 Billion TWD | 45.85% |
2019 | 687.6 Million TWD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 820.22 Million TWD | 2.96% |
2024 Q2 | 820.22 Million TWD | 0.4% |
2023 Q3 | 789.37 Million TWD | -6.72% |
2023 FY | 796.6 Million TWD | -4.94% |
2023 Q1 | 838.53 Million TWD | 0.06% |
2023 Q2 | 846.27 Million TWD | 0.92% |
2023 Q4 | 796.6 Million TWD | 0.92% |
2022 Q4 | 838.04 Million TWD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
GeneFerm Biotechnology Co., Ltd. | 152.07 Million TWD | -423.811% |
Easywell Biomedicals, Inc. | 386.34 Million TWD | -106.192% |
TTY Biopharm Company Limited | 1.91 Billion TWD | 58.403% |
Synmosa Biopharma Corporation | 2.43 Billion TWD | 67.35% |
Orient EuroPharma Co., Ltd. | 4.84 Billion TWD | 83.55% |
Center Laboratories, Inc. | 5.62 Billion TWD | 85.835% |
Tien Liang BioTech Co., Ltd. | 84.65 Million TWD | -840.96% |
Orient Pharma Co., Ltd. | 716.92 Million TWD | -11.114% |
InnoPharmax Inc. | 21.49 Million TWD | -3605.321% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 160.83 Million TWD | -395.307% |
Excelsior Biopharma Inc. | 377.4 Million TWD | -111.075% |
DV Biomed Co., Ltd. | 387.69 Million TWD | -105.472% |
Foresee Pharmaceuticals Co., Ltd. | 228.25 Million TWD | -248.996% |
Handa Pharmaceuticals, Inc. | 13.24 Million TWD | -5916.669% |
UniPharma Co., Ltd. | 277 Thousand TWD | -287483.755% |
Anxo Pharmaceutical Co., Ltd. | 787.84 Million TWD | -1.113% |
Alar Pharmaceuticals Inc. | 1.4 Million TWD | -56437.048% |
Winston Medical Supply Co., Ltd. | 107.32 Million TWD | -642.21% |
Mercury Biopharmaceutical Corporation | 42.34 Million TWD | -1781.053% |
Bioray Biotech Co., Ltd | 69.79 Million TWD | -1041.402% |
TSH Biopharm Corporation Limited | 7.84 Million TWD | -10056.917% |